A randomized, double-blind, 2-treatment, 2-period, crossover phase I study to compare the pharmacokinetics, safety and tolerability of 60 IU/kg of Abcertin, and EU-sourced Cerezyme in healthy volunteers following a single intravenous administration.
Latest Information Update: 06 Apr 2021
At a glance
- Drugs Imiglucerase (Primary)
- Indications Gaucher's disease
- Focus Pharmacokinetics
- Sponsors ISU Abxis
Most Recent Events
- 20 Sep 2020 Status changed from not yet recruiting to completed.
- 15 Oct 2019 New trial record